To ask the Minister for Health the reason pegvaliase, a game-changing medicine for a handful of phenylketonuria patients, has taken more than four years to go through the various stages of the HSE's appraisal process ( and that despite an estimated budget impact of only €700,000 per annum, the HSE Drugs group has recommended against its approval, contradicting the opinion of the expert Rare Disease Technology Review Committee which strongly recommended its approval); where this currently is in the system; the other steps required; when they will be completed; and if he will make a statement on the matter.
Format:PDF|File Size:485KB
